[Achieving optimal antiemetic management].
D000932:Antiemetics / Q000008:administration & dosage* / Q000009:adverse effects; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D006801:Humans; D007262:Infusions, Intravenous; D007546:Isoquinolines / Q000008:administration & dosage* / Q000009:adverse effects; D009325:Nausea / Q000139:chemically induced / Q000451:nursing* / Q000517:prevention & control; D009369:Neoplasms / Q000188:drug therapy / Q000451:nursing*; D017294:Ondansetron / Q000008:administration & dosage / Q000009:adverse effects; D000077924:Palonosetron; D011812:Quinuclidines / Q000008:administration & dosage* / Q000009:adverse effects; D058831:Serotonin 5-HT3 Receptor Antagonists; D014839:Vomiting / Q000139:chemically induced / Q000451:nursing* / Q000517:prevention & control
D000932:Antiemetics; D007546:Isoquinolines; D011812:Quinuclidines; D058831:Serotonin 5-HT3 Receptor Antagonists; D017294:Ondansetron; D000077924:Palonosetron